Board of Directors
Anders Essen-Möller
Chairman
Born in 1941. M.Sc. Founder of and CEO during 1996-2007 of Diamyd Medical and Chairman 2007 –2015. Independent of the Company, major owner. Founder of Synectics Medical AB, sold to Medtronic, Inc. in 1996. Chairman of NextCell Pharma AB.
Holding in Diamyd Medical at August 31, 2025: 1,235,620 Class A shares (of which 100,000 via company), 3,119,040 Class B shares, 327,124 TO 5A, 435,630 TO 5B. Holding in endowment policy: 2,178,152 Class B shares.
Erik Nerpin
Vice Chairman
Born in 1961. Lawyer. Self-employed with Advokatfirman Nerpin AB. Independent of the Company and its principal owners. Board member since 2012. Board assignments in listed companies: Chairman of Kancera AB, Hilbert Group AB, edyoutech AB and Neovici Holding AB and board member in Effnetplattformen Holding AB.
Holding in Diamyd Medical at August 31, 2025: 97,804 Class B shares.
Maria-Teresa Essen-Möller
Board Member
Born in 1970. M.Sc. in Business Administration. Independent to the Company, not independent to its principal owners. Previous experience include CEO of Health Solutions AB, Digital Marketing Manager at Sanofi and Account Director at Creuna. Board member since 2009.
Holding in Diamyd Medical at August 31, 2025: 400,000 Class A shares, 963,998 Class B shares.
Torbjörn Bäckström
Board Member
Born in 1948. MD, PhD. CEO of Umecrine AB. Independent of the Company and its principal owners. Board member since 2017. Head of Neurosteroid Research Centre in Umeå and Professor Emeritus in the Department of Clinical Science, Obstetrics and Gynecology at Umeå University.
Holding in Diamyd Medical at August 31, 2025: 2,342 Class B shares and 468 TO5B via company.
Mark Atkinson
Board Member
Born in 1961. PhD. Professor of Diabetes Research, Department of Pathology, Immunology and Laboratory Medicine, University of Florida, USA. American Diabetes Association Eminent Scholar for Diabetes Research. Director, UF Diabetes Institute, University of Florida. Independent of the Company and its principal owners. Board member since 2018.
Holding in Diamyd Medical at August 31, 2025: 36,750 Class B shares.
Karin Hehenberger
Board Member
Born in 1972. M.D., Ph.D, Karolinska Institute, Post-doc at the Joslin center, Harvard Medical School. Chief Medical Officer, Patient Care America, President and founder of Lyfebulb, Member of the 3B Future Health Ventures Scientific Advisory board, Board member AADI pharmaceuticals (Nasdaq), Board member Anacardio AB, Board member Rolf Luft Foundation for Diabetes research, Board member American Diabetes Association NY/NJ Community Board. Independent to the Company and its principal owners. Board member since 2021.
Holding in Diamyd Medical at August 31, 2025: 10,000 Class B shares.
Karin Rosén
Board Member
Born in 1967. M.D., Ph.D, Lund University, Sweden. More than two decades of experience from senior leadership positions in Global Clinical Development and US & Global Medical Affairs with Horizon Therapeutics, GlaxoSmithKline, Aimmune Therapeutics and Genentech, part of the Roche group. Independent of the Company and its principal owners. Adjunct Board member since March 2023.
Holding in Diamyd Medical at August 31, 2025: 10,000 Class B shares.
Management
Ulf Hannelius
Chief Executive Officer
Born in 1975. PhD in Molecular Biology from Karolinska Institutet in Stockholm and Executive MBA from Stockholm School of Economics. Prior experience from business development in the biotech and medtech industries as well as from academic research in the fields of genetics and molecular biology. Chairman of Diamyd Biomanufacturing AB, Board member in MainlyAI AB. Joined Diamyd Medical in 2015, CEO since 2016.
Holding in Diamyd Medical at August 31, 2025: 463,973 Class B shares, 93,594 TO5B.
Martina Widman
Chief Operating Officer
Born in 1981. M.Sc. in Mechanical Engineering from the Royal Institute of Technology in Stockholm, with a specialization in Biomedical Engineering. Prior experience of clinical operation from the pharmaceutical industry. Joined Diamyd Medical in 2008.
Holding in Diamyd Medical at August 31, 2025: 17,187 Class B shares, 3,437 TO5B.
Niklas Axelsson
Chief Financial Officer
Born in 1973. M.Sc. in Business Administration from Stockholm School of Economics. Prior experience include more than 25 years of work in the pharmaceutical, biotech and investment banking sectors, both in Sweden and internationally. Joined Diamyd Medical in 2025.
Holding in Diamyd Medical at August 31, 2025: 5,000 Class B shares.
Anton Lindqvist
Chief Scientific Officer
Born in 1980. M.Sc in Molecular Biotechnology Engineering from Uppsala University. Research experience from University of Pittsburgh, Uppsala University, the Royal Institute of Technology and Karolinska Institutet. Prior experience in managing technical development at several bio-tech companies. Joined Diamyd Medical in 2013.
Holdings in Diamyd Medical as of August 31, 2025: -
Sofia Mayans
Head of Manufacturing Site
Born in 1976. PhD in Human Genetics from Umeå University. Prior experience from leader positions and business development in the life science sector. Academic research experience in the fields of genetics and immunology from Umeå University, Copenhagen University and La Jolla institute for Immunology. Joined Diamyd Medical in 2024.
Holding in Diamyd Medical at August 31, 2025: 1,422 Class B shares.
Photos by Mattias Bardå, Johan Olsson/Fotograf Johan Olsson AB, Andreas Nilsson and University of Florida